

Marco Fiorillo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6250259/marco-fiorillo-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31
papers

1,324
citations

20
h-index

31
g-index

31
ext. papers

1,638
ext. citations

5
avg, IF

4.59
L-index

#	Paper	IF	Citations
31	Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. <i>Oncotarget</i> , 2015 , 6, 14777-95	3.3	175
30	Graphene oxide selectively targets cancer stem cells, across multiple tumor types: implications for non-toxic cancer treatment, via "differentiation-based nano-therapy". <i>Oncotarget</i> , 2015 , 6, 3553-62	3.3	150
29	Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. <i>Oncotarget</i> , 2016 , 7, 34084-99	3.3	127
28	Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling. <i>Oncotarget</i> , 2015 , 6, 30453-71	3.3	84
27	Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). <i>Aging</i> , 2016 , 8, 1593-607	5.6	83
26	Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy. <i>Oncotarget</i> , 2015 , 6, 14005-25	3.3	76
25	Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2018 , 1859, 984-996	4.6	45
24	Hypocholesterolaemic activity of 3-hydroxy-3-methyl-glutaryl flavanones enriched fraction from bergamot fruit (Citrus bergamia): In vivo studies. <i>Journal of Functional Foods</i> , 2014 , 7, 558-568	5.1	45
23	Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics. <i>Oncotarget</i> , 2017 , 8, 68730-68745	3.2	44
22	Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer. <i>Oncotarget</i> , 2017 , 8, 20309-20327	3.3	43
21	Mass spectrometry-based proteomic approach in <i>Oenococcus oeni</i> enological starter. <i>Journal of Proteome Research</i> , 2014 , 13, 2856-66	5.6	42
20	"Energetic" Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy. <i>Frontiers in Oncology</i> , 2018 , 8, 677	5.3	37
19	Metabolic reprogramming of bone marrow stromal cells by leukemic extracellular vesicles in acute lymphoblastic leukemia. <i>Blood</i> , 2016 , 128, 453-6	2.2	37
18	Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs). <i>Aging</i> , 2019 , 11, 2202-2216	5.6	36
17	A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX. <i>Cell Cycle</i> , 2018 , 17, 2091-2100	4.7	36
16	Bergamot (Citrus bergamia Risso) Flavonoids and Their Potential Benefits in Human Hyperlipidemia and Atherosclerosis: an Overview. <i>Mini-Reviews in Medicinal Chemistry</i> , 2016 , 16, 619-29	3.2	33
15	Estrogen related receptor α (ERR α) a promising target for the therapy of adrenocortical carcinoma (ACC). <i>Oncotarget</i> , 2015 , 6, 25135-48	3.3	32

14	Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast. <i>Oncotarget</i> , 2017 , 8, 67457-67472	3.3	23
13	Thioalbamide, A Thioamidated Peptide from , Affects Tumor Growth and Stemness by Inducing Metabolic Dysfunction and Oxidative Stress. <i>Cells</i> , 2019 , 8,	7.9	23
12	Sericin/Poly(ethylcyanoacrylate) Nanospheres by Interfacial Polymerization for Enhanced Bioefficacy of Fenofibrate: In Vitro and In Vivo Studies. <i>Biomacromolecules</i> , 2015 , 16, 3126-33	6.9	21
11	Deferiprone (DFP) Targets Cancer Stem Cell (CSC) Propagation by Inhibiting Mitochondrial Metabolism and Inducing ROS Production. <i>Cells</i> , 2020 , 9,	7.9	20
10	Hallmarks of the cancer cell of origin: Comparisons with "energetic" cancer stem cells (e-CSCs). <i>Aging</i> , 2019 , 11, 1065-1068	5.6	15
9	The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy. <i>Aging</i> , 2018 , 10, 4000-4023	5.6	15
8	Cholesterol and Mevalonate: Two Metabolites Involved in Breast Cancer Progression and Drug Resistance through the ERR1 Pathway. <i>Cells</i> , 2020 , 9,	7.9	13
7	Mitochondrial Fission Factor (MFF) Inhibits Mitochondrial Metabolism and Reduces Breast Cancer Stem Cell (CSC) Activity. <i>Frontiers in Oncology</i> , 2020 , 10, 1776	5.3	13
6	Enhanced cellular uptake by "pharmaceutically oriented devices" of new simplified analogs of Linezolid with antimicrobial activity. <i>International Journal of Pharmaceutics</i> , 2014 , 461, 163-70	6.5	11
5	FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer. <i>Cancers</i> , 2019 , 11,	6.6	11
4	5-(Carbamoylmethylene)-oxazolidin-2-ones as a Promising Class of Heterocycles Inducing Apoptosis Triggered by Increased ROS Levels and Mitochondrial Dysfunction in Breast and Cervical Cancer. <i>Biomedicines</i> , 2020 , 8,	4.8	10
3	New insights about the structural rearrangements required for substrate translocation in the bovine mitochondrial oxoglutarate carrier. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2016 , 1864, 1473-80	4	10
2	High ATP Production Fuels Cancer Drug Resistance and Metastasis: Implications for Mitochondrial ATP Depletion Therapy. <i>Frontiers in Oncology</i> , 2021 , 11, 740720	5.3	7
1	Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase. <i>Cell Death and Differentiation</i> , 2021 , 28, 2797-2817	12.7	7